Suggested remit: To appraise the clinical and cost effectiveness of chlormethine gel within its marketing authorisation for treating mycosis fungoides-type cutaneous T-cell lymphoma.
Status In progress
Process STA 2018
ID number 1589

Provisional Schedule

Committee meeting: 1 14 July 2020
Expected publication 23 September 2020

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group Health Economics Research Unit and Health Services Research Unit, University of Aberdeen


Companies sponsors Recordati Rare Diseases UK
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Lymphoma Action
Professional groups British Association of Dermatologists
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists


General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
31 October 2019 Invitation to participate
06 August 2019 - 04 September 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
08 May 2019 In progress. Referred 18 March 2019

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance